A biotech company can produce an encouraging laboratory result while still facing years of expense, clinical uncertainty and financing needs. Evaluate two connected questions: what evidence supports the product, and can the business fund the work needed to develop it?
This is an educational framework for reading public information about U.S.-listed companies. It provides no stock picks or forecast of returns. Begin with filings and trial records dated to the period you are examining.
Build a small source packet
Collect the latest annual report, subsequent quarterly reports, material-event filings, trial registry record and the actual results presentation or paper. The SEC's guide to reading a 10-K explains where to find the business description, risk factors, management discussion, financial statements and notes. Use EDGAR to confirm the company and filing date.
Write down the lead asset, disease and patient group, development stage, ownership or licensing terms and the next evidence milestone. Several trials of one molecule can share the same underlying failure risk. A long pipeline graphic may therefore overstate diversification.
For an approved product, investigate sales, expenses, competition, patent and exclusivity disclosures, and commercial obligations. Approval changes the questions; it leaves manufacturing, reimbursement and business execution to be assessed.
Read beyond a positive headline
| Check | What to record | Why it matters |
|---|---|---|
| Population and comparator | Who entered, prior treatment, control treatment and randomization. | A result applies to the studied setting. Historical comparisons may introduce bias. |
| Endpoint | Prespecified primary outcome, timing and analysis population. | A favorable secondary measure can coexist with a failed primary outcome. |
| Magnitude and uncertainty | Absolute results, effect estimate, confidence interval and follow-up. | A headline percentage can hide a small difference or limited precision. |
| Safety and missing data | Adverse events, discontinuations, exclusions and follow-up completeness. | Benefit and harm both affect the product case. |
| Next step | Remaining studies, manufacturing evidence and regulatory process. | A clinical milestone has a different meaning from marketing approval. |
FDA's clinical-research overview explains how trial objectives develop across phases. A phase label helps orient the reader; the protocol and results determine what a particular study establishes. Compare company claims with the registered primary outcome and complete available results.
Estimate runway with explicit assumptions
A simple screening estimate divides usable cash resources by cash used per period. Use the cash-flow statement and relevant notes, distinguish operating cash use from accounting loss, and identify restricted cash, debt payments and unusual cash movements. Quarterly reports often present cumulative year-to-date cash flows: subtract the prior cumulative period when you need a single quarter.
Compare the estimate with management's stated runway and explain the difference. Trials can expand, milestone payments can arrive or fail to arrive, and manufacturing commitments may occur unevenly. A financing plan generally needs room before cash reaches zero.
Understand what a financing changes
Inspect options, warrants, convertible debt, preferred securities and ongoing share-sale programs. Record issuance price, fees, conversion conditions and share-count dates. Market capitalization uses share price times shares outstanding; comparing companies solely by the price of one share misses that scale.
End with a decision record
Write a short evidence-based conclusion: the strongest result, the largest unresolved scientific question, the financing assumptions and the event that would change your assessment. Separate observed facts from management projections and your own estimates.
Use the biotech review worksheet to preserve those distinctions and reproduce both examples. Revisit it after results, financing or a material filing. If you cannot explain the endpoint or reconcile the cash figures, identify that gap before treating the story as an investment thesis.
Also consider portfolio concentration, liquidity and the possibility of losing the entire investment. Diversification can reduce exposure to a single company's failure, while leaving broader market and sector risks.